ALK and non-small cell lung carcinoma: In conclusion, the clinical benefit observed after more than or equal to 5 years of follow-up, coupled with a tolerable and manageable safety profile, confirms alectinib as the standard-of-care treatment for patients with advanced ALK-positive NSCLC.